share_log

Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360 CDx and Guardant360 TissueNext as Companion Diagnostics for Positive Non-Small Cell Lung Cancer

Benzinga Real-time News ·  Feb 2, 2023 08:10

Collaboration is Guardant Health's first to explore both tissue- and blood-based assays as companion diagnostics (CDx). Taletrectinib is an investigational ROS1 inhibitor for the treatment of adult patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment